Hepatitis Monthly

Published by: Kowsar

Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma

Shawky Abdelhamid Fouad 1 , * , Nagwa Abdel Ghaffar Mohamed 2 , Mary Wadie Fawzy 1 and Doaa Ali Moustafa 1
Authors Information
1 Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Clinical and Chemical Pathology, National Research Center, Giza, Egypt
Article information
  • Hepatitis Monthly: September 01, 2015, 15 (9); e30753
  • Published Online: September 1, 2015
  • Article Type: Research Article
  • Received: June 14, 2015
  • Revised: July 31, 2015
  • Accepted: August 16, 2015
  • DOI: 10.5812/hepatmon.30753

To Cite: Fouad S A, Mohamed N A G, Fawzy M W, Moustafa D A. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma, Hepat Mon. 2015 ; 15(9):e30753. doi: 10.5812/hepatmon.30753.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014; 44(1): 22-30[DOI][PubMed]
  • 2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287(5454): 860-4[PubMed]
  • 3. Suzuki H, Amizuka N, Oda K, Li M, Yoshie H, Ohshima H, et al. Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol. 2005; 68(5): 371-81[PubMed]
  • 4. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7(15): 1475-82[PubMed]
  • 5. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta. 2010; 411(9-10): 675-8[DOI][PubMed]
  • 6. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007; 56(6): 782-9[DOI][PubMed]
  • 7. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011; 53(1): 106-15[DOI][PubMed]
  • 8. Ranjbar Kermani F, Sharifi Z, Ferdowsian F, Paz Z, Tavassoli F. The Usefulness of Anti-HCV Signal to Cut-off Ratio in Predicting Viremia in Anti-HCV in Patients With Hepatitis C Virus Infection. Jundishapur J Microbiol. 2015; 8(4)
  • 9. Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, et al. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013; 13(6)[DOI][PubMed]
  • 10. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2): 153-6[PubMed]
  • 11. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001; 1(3): 197-203[PubMed]
  • 12. El-Zanaty F, Wany A. Egypt Demographic and Health Survey 2008. 2009;
  • 13. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[DOI][PubMed]
  • 14. Bruix J, Sherman M, Practice Guidelines Committee AAFTSOLD. Management of hepatocellular carcinoma. Hepatology. 2005; 42(5): 1208-36[DOI][PubMed]
  • 15. Ostheimer C, Bache M, Guttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014; 14: 858[DOI][PubMed]
  • 16. Fouad SA, Elsaaid NH, Mohamed NA, Abutaleb OM. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIalpha in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. Hepat Mon. 2014; 14(9)[DOI][PubMed]
  • 17. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366(3): 216-24[DOI][PubMed]
  • 18. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol . 2006; 101(8): 1939
  • 19. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012; 55(2): 483-90[DOI][PubMed]
  • 20. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res. 2004; 29(4): 202-6[DOI][PubMed]
  • 21. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer. 2008; 44(7): 1000-6[DOI][PubMed]
  • 22. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006; 101(9): 2051-9[DOI][PubMed]
  • 23. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008; 103(1): 4-13[DOI][PubMed]
  • 24. Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama. 2002; 56(6): 317-20[PubMed]
  • 25. Gad A, Tanaka E, Matsumoto A, El-Hamid Serwah A, Attia F, Hassan A, et al. Ethnicity affects the diagnostic validity of alpha-fetoprotein in hepatocellular carcinoma. Asia-Pacific J Clin Oncol. 2005; 1(2-3): 64-70[DOI]
  • 26. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008; 62(7): 1056-62[DOI][PubMed]
  • 27. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2012; 130(11): 2685-92[DOI][PubMed]
  • 28. Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2013; 45(1): 58-62[DOI][PubMed]
  • 29. El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res. 2010; 41(7): 541-7[DOI][PubMed]
  • 30. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol. 2011; 10(3): 296-305[PubMed]
  • 31. Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014; 15(3-4): 103-7[DOI][PubMed]
  • 32. Keddeas MW, Abo-shady RA. Evaluation of plasma osteopontin level as a biomarker for hepatocellular carcinoma in Egyptian patients. Egypt Liver J. 2011; 1(1): 38-42[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments